Antibody-mediated blockade of programmed cell death protein 1 (PD-1) or cell-surface localized programmed cell death-ligand 1 (PD-L1) provides a novel therapeutic paradigm for patients with advanced NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.